Personalized Therapy for Multiple Myeloma
This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews
- PDF / 2,201,765 Bytes
- 183 Pages / 439.43 x 683.15 pts Page_size
- 42 Downloads / 209 Views
Saad Z. Usmani Ajay K. Nooka Editors
123
Personalized Therapy for Multiple Myeloma
Saad Z. Usmani • Ajay K. Nooka Editors
Personalized Therapy for Multiple Myeloma
Editors Saad Z. Usmani Department of Hematologic Oncology and Blood Levine Cancer Institute Charlotte, North Carolina USA
Ajay K. Nooka Department of Hematology and Oncology Winship Cancer Institute of Emory University Atlanta, Georgia USA
ISBN 978-3-319-61871-5 ISBN 978-3-319-61872-2 (eBook) https://doi.org/10.1007/978-3-319-61872-2 Library of Congress Control Number: 2017951926 © Springer International Publishing AG 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
This book is dedicated to our patients, their caregivers, and our families.
Preface
The management of multiple myeloma (MM) has evolved tremendously over the last decade, from being an orphan disease with limited treatment options to a disease that can be chronically managed for most patients. The knowledge of the heterogenous disease biology and development of novel drug classes (immunomodulatory drugs, proteasome inhibitors, etc.) that target this disease have resulted in more than doubling the overall survival for MM patients. There is a recognition that MM has several different molecular/clinical phenotypes and that several genomic subclones exist in any given patient—clearly, MM is not a one-pathway disease. Given such variability, a cookie-cutter approach may not be applicable to MM, and many factors influence treatment strategies for a given patient. Several long-standing paradigms are being shifted, and such changes are coming at a rapid pace. We know that monoclonal gammopathy of undeterm
Data Loading...
